CTRI Number |
CTRI/2020/05/025270 [Registered on: 20/05/2020] Trial Registered Prospectively |
Last Modified On: |
13/05/2020 |
Post Graduate Thesis |
Yes |
Type of Trial |
Interventional |
Type of Study
|
Drug |
Study Design |
Randomized, Parallel Group, Active Controlled Trial |
Public Title of Study
|
A study to compare effect of azithromycin versus empirical treatment in acute encephalitis syndrome |
Scientific Title of Study
|
Effect of intravenous Azithromycin as adjunctive empirical treatment in children with acute encephalitis syndrome
|
Trial Acronym |
|
Secondary IDs if Any
|
Secondary ID |
Identifier |
NIL |
NIL |
|
Details of Principal Investigator or overall Trial Coordinator (multi-center study)
|
Name |
KUNDAN MITTAL |
Designation |
SENIOR PROFESSOR |
Affiliation |
PT BD SHARMA PGIMS ROHTAK |
Address |
Office of Head of department of Pediatrics, ward-14, Pt B D Sharma
Postgraduate Institute of Medical Sciences, Rohtak
Rohtak
Rohtak HARYANA 124001 India |
Phone |
|
Fax |
|
Email |
kundanmittal@gmail.com |
|
Details of Contact Person Scientific Query
|
Name |
KUNDAN MITTAL |
Designation |
SENIOR PROFESSOR |
Affiliation |
PT BD SHARMA PGIMS ROHTAK |
Address |
Office of Head of department of Pediatrics, ward-14, Pt B D Sharma
Postgraduate Institute of Medical Sciences, Rohtak
Rohtak
Rohtak HARYANA 124001 India |
Phone |
|
Fax |
|
Email |
kundanmittal@gmail.com |
|
Details of Contact Person Public Query
|
Name |
PRITI YADAV |
Designation |
POST GRADUATE RESIDENT |
Affiliation |
PGIMS ROHTAK |
Address |
Office of Head of department of Pediatrics, ward-14, Pt B D Sharma
Postgraduate Institute of Medical Sciences, Rohtak
Rohtak ROHTAK HARYANA Rohtak HARYANA 124001 India |
Phone |
7838754501 |
Fax |
|
Email |
prityadav@gmail.com |
|
Source of Monetary or Material Support
|
PT BD SHARMA POST GRADUATE INSTITUTE OF MEDICAL SCIENCES ROHTAK HARYANA-124001 |
|
Primary Sponsor
|
Name |
KUNDAN MITTAL |
Address |
Office of Head of department of Pediatrics, ward-14, Pt B D Sharma
Postgraduate Institute of Medical Sciences, Rohtak
Rohtak
HARYANA
124001
India |
Type of Sponsor |
Other [SELF] |
|
Details of Secondary Sponsor
|
|
Countries of Recruitment
|
India |
Sites of Study
|
No of Sites = 1 |
Name of Principal
Investigator |
Name of Site |
Site Address |
Phone/Fax/Email |
PRITI YADAV |
Pt B D Sharma Postgraduate Institute of Medical Sciences, Rohtak |
Emergency, ward-14, ward-16, PICU of department of paediatrics, Pt B D Sharma
Postgraduate Institute of Medical Sciences, rohtak Rohtak HARYANA |
7838754501
prityadav12@gmail.com |
|
Details of Ethics Committee
|
No of Ethics Committees= 1 |
Name of Committee |
Approval Status |
INSTITUTIONAL ETHICAL COMMITTEE PT BD SHARMA PGIMS ROHTAK |
Approved |
|
Regulatory Clearance Status from DCGI
|
|
Health Condition / Problems Studied
|
Health Type |
Condition |
Patients |
(1) ICD-10 Condition: G049||Encephalitis, myelitis and encephalomyelitis, unspecified, |
|
Intervention / Comparator Agent
|
Type |
Name |
Details |
Comparator Agent |
conventional treatment that is intravenous ceftriaxone, acyclovir, vancomycin, artesunate |
a. Intravenous Ceftriaxone (100 mg/kg/day in 2 divided doses)
b.Intravenous Vancomycin (60 mg/kg/day in 4 divided doses)
c.Intravenous acyclovir (20 mg/kg/dose every 8 hours) [To be stopped once CSF HSV PCR is negative]
d. IV artesunate: 2.4-3 mg/kg once a day to be stopped if peripheral smear for malarial parasite is negative
|
Intervention |
Intravenous azithromycin |
Intravenous Azithromycin would be given in the dose of 10mg/kg over 5 days in addition to conventional treatment |
|
Inclusion Criteria
|
Age From |
1.00 Year(s) |
Age To |
14.00 Year(s) |
Gender |
Both |
Details |
Presence of altered mental status with at least three of the following: fever (>38 C) lasting for more than 72 hours before or after presentation; generalized or focal seizure not attributable to preexisting seizure disorder; new onset of focal neurological deficit; CSF pleocytosis> 5/cumm; abnormality of brain parenchyma on neuro imaging suggestive of encephalitis that is acute in onset or new from prior studies; abnormality on electroencephalography that is consistent with encephalitis and not attributable to another cause, coma, or inability to talk. |
|
ExclusionCriteria |
Details |
- Children with prior developmental delay or intellectual disability
- Children with known renal, pulmonary, cardiac or hepatic dysfunction.
- Children with suspected inborn errors of metabolism
- Children with toxic encephalopathy or traumatic brain injury
- Children who have hemorrhagic or ischemic stroke
- Children with clinical and laboratory evidence of multi-organ dysfunction at hospital admission
- Children who have already received treatment other than conventional treatment including Azithromycin or steroids
- Children having high clinical suspicion of bacterial meningitis or TB meningitis
- Children with a contraindication to Azithromycin or albumin
- Children with known hyper coagulable state
|
|
Method of Generating Random Sequence
|
Computer generated randomization |
Method of Concealment
|
Sequentially numbered, sealed, opaque envelopes |
Blinding/Masking
|
Open Label |
Primary Outcome
|
Outcome |
TimePoints |
Proportion of children who expired (Mortality) |
during hospital stay upto discharge |
|
Secondary Outcome
|
Outcome |
TimePoints |
1. Proportion of children with significant disability as determined by Liverpool outcome score (LOS) at discharge
2. Proportion of children with at least one serious adverse event
3. Degree of impairment in terms of International Classification of Functioning, Disability, and Health-Children and Youth Version (ICF-CY)
4. Total length of hospital stay in days |
AT TIME OF DISCHARGE |
|
Target Sample Size
|
Total Sample Size="60" Sample Size from India="60"
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" |
Phase of Trial
|
N/A |
Date of First Enrollment (India)
|
20/05/2020 |
Date of Study Completion (India) |
Applicable only for Completed/Terminated trials |
Date of First Enrollment (Global) |
Date Missing |
Date of Study Completion (Global) |
Applicable only for Completed/Terminated trials |
Estimated Duration of Trial
|
Years="1" Months="0" Days="0" |
Recruitment Status of Trial (Global)
|
Not Applicable |
Recruitment Status of Trial (India) |
Not Yet Recruiting |
Publication Details
|
RECRUITMENT NOT STARTED |
Individual Participant Data (IPD) Sharing Statement
|
Will individual participant data (IPD) be shared publicly (including data dictionaries)?
|
Brief Summary
|
The eligible
participants will be enrolled consecutively. A predesigned case record form
will be filled. Each eligible child will be subjected to
demographic details (age, gender, socioeconomic status). A detailed history
will be recorded. Complete neurological examination would be performed. All
eligible participants would be admitted in Pediatric Intensive Care Unit.
Management of children with acute encephalitis would be as per the standard
protocol. Eligible participants would be randomized into interventional
group (Azithromycin plus conventional treatment) and control group
(conventional treatment).
Intervention group will be given Azithromycin plus
conventional treatment and in control group only conventional treatment will be given.
Intravenous Azithromycin
would be given in the dose of 10mg/kg over 5 days. Adverse events if any would
be managed symptomatically and recorded. Conventional
empirical treatment of acute encephalitis syndrome will be as per the consensus
guidelines on evaluation and management of suspected acute encephalitis in
children in India.
1. Management
of seizures with anti epileptic medication.
2. Management
to decrease raised intracranial pressure:3% Nacl or Mannitol
3. Antimicrobial
protocol:
a.
Intravenous Ceftriaxone (100
mg/kg/day in 2 divided doses)
b.
Intravenous Vancomycin (60 mg/kg/day
in 4 divided doses)
c.
Intravenous acyclovir (20 mg/kg/dose
every 8 hours) [To be stopped once CSF HSV PCR is negative]
d.
IV artesunate: 2.4-3 mg/kg once a day to be stopped if peripheral
smear for malarial parasite is negative
4. Management of
associated systemic complication as per standard PICU protocol.
Vital signs
including heart rate, respiratory rate, mean arterial pressure would be
recorded at least every 6 hourly. Level of consciousness in terms of Glasgow
coma score and four scores will be evaluated every 6 hourly respiratory
pattern, presence of oculo cephalic reflex, pupil size and reaction, brainstem
function, fundus evaluation would be recorded at-least every 12 hourly. Need
for mechanical ventilation, need for inotropic support, evidence of multi-organ
dysfunction would be recorded. Once the patient is hemodynamically stable and feeding
has been established, the patient would be shifted to the ward. Any adverse
event following drug administration would be recorded. Common adverse events
that would be recorded include fever, dyspnea, vomiting, irritable, skin rash,
hypotension, Malena.
Neuroimaging including MRI Brain and EEG would be
performed as soon as the patient is hemodynamically stable. Blood sample would
be obtained for ELISA for scrub typhus, HIV serology and for obtaining thick
and thin peripheral smear for malarial parasite. Cerebrospinal fluid (CSF) [5
ml] would be obtained for testing for Japanese encephalitis using ELISA.
Glasgow coma score, FOUR scores, Liverpool outcome score, ICF-CY scoring will
be performed at the time of discharge. |